FDA Removes BPC 157, TB 500 and 10 More Peptides from Category 2 (April 2026) FDA's Bulks List: Section 503A Peptide power laws Chief Longevity Officer BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved This is one of the biggest peptide regulatory updates in years, and it's just the beginning. The FDA has officially initiated the first step to reverse its 2023 stance, removing 12 peptides The FDA just changed the rules on peptides effective April 15, 2026. BPC 157, GHK Cu, MOTS C, and TB 500 have been removed from the Category 2 restricted compounding list. Here is what